Gain Therapeutics (NASDAQ:GANX - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect Gain Therapeutics to post earnings of ($0.16) per share for the quarter.
Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.07. On average, analysts expect Gain Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Gain Therapeutics Price Performance
Shares of Gain Therapeutics stock traded down $0.09 during trading on Friday, reaching $1.94. The company's stock had a trading volume of 94,601 shares, compared to its average volume of 305,536. The stock has a 50-day moving average price of $1.94 and a two-hundred day moving average price of $2.03. The stock has a market capitalization of $57.09 million, a P/E ratio of -1.76 and a beta of 0.17. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a one year low of $0.89 and a one year high of $3.19.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on GANX shares. HC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of Gain Therapeutics in a report on Monday, March 17th. Scotiabank began coverage on Gain Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $12.00 target price for the company. Finally, Chardan Capital reiterated a "buy" rating and issued a $6.00 price target on shares of Gain Therapeutics in a report on Friday, March 28th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $8.20.
View Our Latest Stock Report on GANX
About Gain Therapeutics
(
Get Free Report)
Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Featured Stories
Before you consider Gain Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gain Therapeutics wasn't on the list.
While Gain Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
